Travere Therapeutics shares are trading higher after the company announced the completion of a successful pre-NDA meeting with the FDA for FILSPARI in IgA nephropathy and provided regulatory updates for both IgAN and FSGS.
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics' stock is up following a positive pre-NDA meeting with the FDA regarding FILSPARI for IgA nephropathy, along with regulatory updates for IgAN and FSGS.
December 05, 2023 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics' shares are up after a successful pre-NDA meeting with the FDA for FILSPARI in IgA nephropathy, indicating a positive regulatory milestone.
The successful pre-NDA meeting suggests that FILSPARI is on track for potential approval, which is a significant positive development for Travere Therapeutics. This regulatory milestone typically leads to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100